University spinoff seeking to reduce chronic pelvic pain and painful sex for females. Cervu is developing a therapy product to address chronic pelvic pain and dyspareunia, conditions affecting a significant portion of women, especially female cancer survivors. The technology is supported by NCSU and UNC, with a provisional patent filed for exclusive licensing to Cervu. The company aims to provide a direct-to-consumer non-regulated path to market initially, with potential future FDA clearance and insurance coverage.